You are kindly invited to attend our webinar "Early Sepsis Diagnosis & Management" taking place on Friday April 23rd 8.45 am
Sepsis is a life-threatening organ dysfunction caused by a dysregulated immune response to infection. Sepsis has a high mortality rate making it a significant global healthcare concern, killing more individuals than prostate cancer, breast cancer and HIV/AIDS combined
This webinar shows how Beckman Coulter uses a multidisciplinary approach for sepsis diagnosis using different biomarkers within the whole clinical laboratory. The combination of different laboratory disciplines allows clinicians to speed-up decision making at every stage of the sepsis identification and treatment path.
If you need more information, don't hesitate to contact our experts Damien Siemons DSS@ANALIS.BE - Ronald Bailly RBY@ANALIS.BE - Geert CLAEYS GCS@ANALIS.BE
|
PROGRAM
8.45 WELCOME & INTRODUCTION |
9.00 Monocyte distribution width: new biomarker for sepsis diagnosis.
Damien Simoens – Product Manager Cellular Biology - Analis Elena Sukhacheva - Director Medical and Scientific Affairs Beckman Coulter
Review of the evaluation studies of the new biomarker for an early sepsis indication: MDW (Monocytes Distribution Width). Overview of how to perform the test with the DxH900 Hematology Analyzer. Short introduction about a fast and simple test in flow cytometry to discriminate the immune response to a viral or to a bacterial stimuli. |
10.00 Confirmatory tests using clinical chemistry & immunoassay biomarkers.
Ronald Bailly – Product Manager Clinical Chemistry & ImmunoAssays - Analis
Review of the main sepsis biomarkers in suspected inflamation or infection, as well as biochemical tests to monitor the effectiveness of treatment. |
11.00 Rapid & direct antimicrobial susceptibility testing from positive blood cultures. Guillermo Martín Gutiérrez - Hospital Universitario Virgen del Rocío, of Sevilla
How to obtain directly antimicrobial susceptibility testing (AST) from positive blood cultures? Including an evaluation study with the NEG MULTIDRUG RESISTANCE MIC1 panel from Beckman for rapid antimicrobial susceptibility testing, with the objective of detecting antimicrobial resistance in 8-12 hours in Pseudomonas aeruginosa , specifically in non-carbapenemase-mediated carbapenem resistant P. aeruginosa (CRPA). |
12.00 DEMO: ESCAVO Mobile Clinical App for Sepsis With up-to-date clinical information regarding sepsis detection and patient management available in an instant, the app is used worldwide as a treatment reference. - Evidence-based resources for the Emergency Department (ED) - Access authoritative sources in the field of sepsis in busy acute- and critical-care settings - Valuable learning points distilled from a large body of medical literature in a concise, easy-to-use format - Reference evidence-based resources from authoritative sources
|
|
---|
|
|